Emergent BioSolutions filings document an operating public-health company with NYSE-listed common stock under the symbol EBS. Its Form 8-K reports cover financial results, investor presentations, Regulation FD materials, debt prepayments, credit agreements, and other capital-structure events tied to its term loan and asset-based revolving facility.
Proxy and annual-meeting filings describe board elections, director appointments, committee service, auditor ratification, executive compensation, equity awards, and stockholder voting results. The filing record also captures governance disclosures for a company supplying NARCAN® Nasal Spray, ACAM2000®, and other medical countermeasure and bioservices products.
Emergent BioSolutions SVP, Bioservices William Hartzel reported routine equity award adjustments and tax withholding transactions in company stock. On February 6, 2026, 5,771 performance stock units tied to 2023–2025 goals were disposed of after the Compensation Committee certified performance at 25% of target, resulting in a smaller share payout than originally reported.
On the same date, 630 shares of common stock were withheld to cover taxes on vested restricted stock units. After these transactions, Hartzel directly owned 96,681 shares of Emergent BioSolutions common stock.
Emergent BioSolutions EVP and CFO Richard S. Lindahl reported equity award activity tied to performance stock units and tax withholding. On February 6, 2026, he disposed of 46,155 shares of common stock at $10.92 per share and had 245,342 shares beneficially owned immediately afterward.
The filing explains that 2023–2025 performance stock units under the company’s stock incentive plan were certified at 25% of target, resulting in an actual award of 15,384 shares of common stock. In a separate transaction the same day, 5,642 shares at $10.92 per share were withheld to cover taxes on vesting, leaving Lindahl with 239,700 directly owned shares.
State Street Corporation has disclosed a passive stake in Emergent BioSolutions Inc. The firm reports beneficial ownership of 2,696,375 shares of Emergent BioSolutions common stock, representing 5.1% of the class as of 12/31/2025.
State Street reports no sole voting or dispositive power. It has shared voting power over 2,493,618 shares and shared dispositive power over 2,696,375 shares, reflecting holdings managed through affiliated asset management subsidiaries in the ordinary course of business, without any intent to change or influence control of the company.
The Vanguard Group filed an amended ownership report showing it beneficially owns 3,553,999 shares of Emergent BioSolutions Inc. common stock, representing 6.76% of the class. Vanguard reports shared voting power over 356,748 shares and shared dispositive power over all 3,553,999 shares, with no sole voting or dispositive power.
Vanguard notes an internal realignment effective January 12, 2026, after which certain subsidiaries or business divisions are expected to report beneficial ownership separately while pursuing the same investment strategies. The securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Emergent BioSolutions.
Emergent BioSolutions Inc. reported that its president and chief executive officer, Joseph C. Papa, is presenting at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company made available an investor presentation, furnished as Exhibit 99.1 to this Form 8-K, which contains the slides used for the event.
The information in Item 7.01 and Exhibit 99.1 is being furnished, not filed, so it is not subject to liability under Section 18 of the Exchange Act and is not automatically incorporated into Securities Act or Exchange Act filings unless specifically stated otherwise.
Emergent BioSolutions Inc. disclosed that it voluntarily prepaid $100 million in late December 2025 on its outstanding term loan under a credit agreement dated August 30, 2024. This early repayment reduces the company’s term loan balance and interest-bearing debt under that facility. The company announced the prepayment in a press release furnished as an exhibit, indicating a proactive step in managing its capital structure and obligations to its lenders.
An insider of EBS has filed a Rule 144 notice to sell 25,748 common shares. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $360,142.43, and the issuer has 52,519,964 common shares outstanding.
The 25,748 shares were acquired from the issuer on 01/07/2026 via a stock option exercise paid in cash on the same date. The filing also reports that Louis W Sullivan sold 104,695 common shares during the past three months for gross proceeds of $1,336,462.98.
EBS has filed a notice under Rule 144 for a proposed sale of 104,695 shares of common stock, with an aggregate market value of $1,336,462.98. These shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on the NYSE, with an approximate sale date of 12/22/2025. The issuer had 52,519,964 shares of common stock outstanding, providing context for the size of this planned sale. The securities being sold were originally acquired as restricted stock on 05/18/2016 and as exercised shares on 05/10/2021, both from the issuer.
Emergent BioSolutions reported an insider transaction by an officer serving as senior vice president of R&D and chief medical officer. On December 14, 2025, 3,543 shares of common stock were withheld at a price of $11.41 per share to pay taxes due when restricted stock units vested and settled.
After this tax withholding, the officer directly beneficially owns 88,439 shares of Emergent BioSolutions common stock.
Emergent BioSolutions Inc. announced that it has received approval from the U.S. Food and Drug Administration for drug product manufacturing of raxibacumab at its Winnipeg manufacturing site. This means the company is now authorized to produce this product at that facility, which supports its medical countermeasures business focused on serious public health threats. The update was shared through a press release furnished as an exhibit, and the information is presented as a Regulation FD disclosure rather than as part of the company’s audited financial statements.